Sucroferric oxyhydroxide (Velphoro®) is recommended as an option for restricted use within its licensed indication within NHS Wales for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velphoro®) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease. Sucroferric oxyhydroxide (Velphoro®) should be restricted as an option for use where non-calcium based phosphate binders are considered appropriate. Sucroferric oxyhydroxide (Velphoro®) is not recommended for use within NHS Wales outside of this subpopulation.